Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis

被引:13
作者
Ji, Kun [1 ]
Ma, Jianling [1 ]
Wang, Liangmin [1 ]
Li, Niuniu [1 ]
Dong, Shangjuan [1 ]
Shi, Liqing [1 ]
机构
[1] Beijing Univ Tradit Chinese Med, Dongfang Hosp, Dept Resp Med, Beijing 100078, Peoples R China
基金
中国国家自然科学基金;
关键词
EPIDEMIOLOGY; SURVIVAL; TRIAL;
D O I
10.1155/2020/1752387
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other measurements and reduced SGRQ scores (SMD = - 0.51, 95% CI - 0.70 to - 0.22, p < 0.001). Subgroup analysis of different study durations (3 months, >= 6 months) and comparison models (TCM vs. WM, TCM+ WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27-1.60, p = 0.352). *ere was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. Conclusion. To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.
引用
收藏
页数:11
相关论文
共 50 条
[31]   Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis [J].
Qiu, Meihua ;
Chen, Yuqing ;
Ye, Qiao .
CLINICAL RESPIRATORY JOURNAL, 2018, 12 (03) :1084-1092
[32]   Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis [J].
Wang, Haoyu ;
Yang, Ruiyuan ;
Jin, Jing ;
Wang, Zhoufeng ;
Li, Weimin .
PLOS ONE, 2021, 16 (11)
[33]   Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis [J].
Di Martino, Enrica ;
Provenzani, Alessio ;
Vitulo, Patrizio ;
Polidori, Piera .
ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) :723-731
[34]   Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis A Systematic Review and Meta-Analysis [J].
Fidler, Lee ;
Sitzer, Nicole ;
Shapera, Shane ;
Shah, Prakesh S. .
CHEST, 2018, 153 (06) :1405-1415
[35]   Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis [J].
Hu, Jiaqi ;
Jiang, Juling ;
Liu, Rui ;
Cheng, Mengqi ;
Zhu, Guanghui ;
He, Shulin ;
Shi, Bolun ;
Zhao, Yuwei ;
He, Zhongning ;
Yu, Huibo ;
Zhang, Xing ;
Zheng, Honggang ;
Hua, Baojin .
FRONTIERS IN ONCOLOGY, 2022, 12
[36]   Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis [J].
Kamiya, Hiroyuki ;
Panlaqui, Ogee Mer .
BMJ OPEN, 2020, 10 (06)
[37]   Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis [J].
Qiu, Yiting ;
Ye, Wei .
ANNALS OF THORACIC MEDICINE, 2025, 20 (03)
[38]   Efficacy and Safety of Astragalus-Containing Traditional Chinese Medicine Combined With Platinum-Based Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis [J].
Cheng, Mengqi ;
Hu, Jiaqi ;
Zhao, Yuwei ;
Jiang, Juling ;
Qi, Runzhi ;
Chen, Shuntai ;
Li, Yaoyuan ;
Zheng, Honggang ;
Liu, Rui ;
Guo, Qiujun ;
Zhang, Xing ;
Qin, Yinggang ;
Hua, Baojin .
FRONTIERS IN ONCOLOGY, 2021, 11
[39]   Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis [J].
Finnerty, James Patrick ;
Ponnuswamy, Aravind ;
Dutta, Prosjenjit ;
Abdelaziz, Ammar ;
Kamil, Hafiz .
BMC PULMONARY MEDICINE, 2021, 21 (01)
[40]   The efficacy of ginseng-containing traditional Chinese medicine in patients with acute decompensated heart failure: A systematic review and meta-analysis [J].
Chen, Xiaozhe ;
Ma, Yulong ;
Li, Jianhua ;
Yao, Lei ;
Gui, Mingtai ;
Lu, Bo ;
Zhou, Xunjie ;
Wang, Mingzhu ;
Fu, Deyu .
FRONTIERS IN PHARMACOLOGY, 2023, 13